Xu, Shao-Kun published the artcileEffects of the valsartan/amlodipine combination and nifedipine gastrointestinal therapeutic system monotherapy on brachial pulse pressure and radial augmentation index in hypertensive patients., HPLC of Formula: 21829-25-4, the main research area is .
OBJECTIVE: In a substudy of a randomized controlled trial, we investigated the effects of the valsartan/amlodipine single-pill combination and nifedipine gastrointestinal therapeutic system (GITS) monotherapy on brachial pulse pressure (bPP) and radial augmentation index (rAI) in patients with previously uncontrolled hypertension. METHODS: We performed measurements of clinic blood pressure (BP) and pulse rate and rAI (nâ?â?3) and ambulatory BP monitoring (nâ?â?2) at baseline and 12-week of follow-up. Analysis of covariance was performed to calculate the least square mean change from baseline and between-group differences [95% confidence interval (CI)]. Correlation analysis was performed to study the interrelationship between the changes in bPP and rAI and in pulse rate. RESULTS: After 12-week treatment, clinic and ambulatory SBP/DBP and pulse rate were not differently changed between the valsartan/amlodipine (nâ?â?9) and nifedipine GITS groups (nâ?â?4, Pââ¥â?.06) except daytime SBP (Pâ?â?.01). The reductions in 24-h and daytime ambulatory bPP were significantly greater in the former than the latter group (Pââ¤â?.04). rAI increased slightly by 3.5% (Pâ?â?.20) and 5.2% (Pâ?â?.06) in the valsartan/amlodipine and nifedipine groups, respectively, with a between-group difference of -1.7% (95% CI -9.6 to 6.1%, Pâ?â?.66). In the two groups combined, the changes in clinic and ambulatory bPP were not or weakly associated with that in clinic or ambulatory pulse rate (râ?â?0.14 to 0.36, Pâ?â?.02-0.95), while the changes in rAI were more strongly or significantly associated with that in clinic or ambulatory pulse rate (râ?â?0.39 to -0.23, Pâ?â?.02-0.16). CONCLUSIONS: Antihypertensive drug-induced changes in rAI but not bPP were dependent on pulse rate.
Blood pressure monitoring published new progress in MEDLINE about 21829-25-4, 21829-25-4 belongs to class pyridine-derivatives, name is Dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, and the molecular formula is C17H18N2O6, HPLC of Formula: 21829-25-4.